finance

Health Tech By STAT staff

The health tech tracker for the second quarter: 15 pivotal industry events to watch

Pharma By Olivia Goldhill

Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich

Biotech By Kate Sheridan

Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives

Health Tech By Casey Ross

How the wave of telehealth SPACs during the pandemic could create a ‘perfect storm’ for investors

Health Tech By Erin Brodwin

Cigna’s Evernorth to acquire telehealth company MDLive

Pharmalot By Ed Silverman

Once again, the credit outlook for the pharmaceutical industry is negative

Pharmalot By Ed Silverman

Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline

Special Report By Kate Sheridan

At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness

Health Tech By Mario Aguilar

Zocdoc, staking its future on the promise of hybrid care, raises $150 million

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring

Health Tech By Casey Ross and Matthew Herper

23andMe to go public via Richard Branson’s SPAC

Pharmalot By Ed Silverman

Will the FTC get tougher on pharma business practices under the Biden administration?

Health Tech By Mario Aguilar

What comes after the telehealth boom? Hybrid care models draw investor interest

Biotech By Kate Sheridan and Adam Feuerstein

After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics 

Politics By Lev Facher

Major health companies and trade groups suspend campaign contributions after Capitol riot

Something Ventured By Kate Sheridan

Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?

Health Tech By Erin Brodwin

Haven, ambitious health venture backed by Amazon, to shut down

First Opinion By Bob Kocher and Bryan Roberts

Incentives and information drive health care innovation: lessons from Medicare Advantage

First Opinion By Til Schuermann and Helen Leis

We stress tested banks in 2009. We need to do the same thing now for U.S. hospital systems

Biotech By Damian Garde

How 2020 became the year of the biotech SPAC

Biotech By Kate Sheridan

The most impressive biotech VCs of 2020 

Biotech By Adam Feuerstein and Matthew Herper

AstraZeneca to acquire Alexion for $39 billion, adding blockbuster immune medicines

First Opinion By Cecile Riboud

In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment

Biotech By Kate Sheridan

Months of limbo at OpenBiome put fecal matter transplants on hold across the country

Biotech By Kate Sheridan

Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles